Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Williams TM, Ciccarone TM, MacTough SC, Bock RL, Conner MW, Davide JP, Hamilton K, Koblan KS, Kohl NE, Kral AM, Mosser SD, Omer CA, Pompliano DL, Rands E, Schaber MD, Shah D, Wilson FR, Gibbs JB, Graham SL, Hartman GD, Oliff AI, Smith RL. Williams TM, et al. Among authors: wilson fr. J Med Chem. 1996 Mar 29;39(7):1345-8. doi: 10.1021/jm9508090. J Med Chem. 1996. PMID: 8691462 No abstract available.
Extending the SUSI peatland simulator to include dissolved organic carbon formation, transport and biodegradation - Proper water management reduces lateral carbon fluxes and improves carbon balance.
Palviainen M, Pumpanen J, Mosquera V, Hasselquist EM, Laudon H, Ostonen I, Kull A, Wilson FR, Peltomaa E, Könönen M, Launiainen S, Peltola H, Ojala A, Laurén A. Palviainen M, et al. Among authors: wilson fr. Sci Total Environ. 2024 Nov 10;950:175173. doi: 10.1016/j.scitotenv.2024.175173. Epub 2024 Aug 6. Sci Total Environ. 2024. PMID: 39117189 Free article.
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Feliciano JL, McLoone D, Xu Y, Quek RGW, Kuznik A, Pouliot JF, Gullo G, Rietschel P, Guyot P, Konidaris G, Chan K, Keeping S, Wilson FR, Freemantle N. Feliciano JL, et al. Among authors: wilson fr. Front Oncol. 2023 Apr 4;12:1081729. doi: 10.3389/fonc.2022.1081729. eCollection 2022. Front Oncol. 2023. PMID: 37082098 Free PMC article.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N, Xu Y, Wilson FR, Guyot P, Chen CI, Keeping S, Konidaris G, Chan K, Kuznik A, Atsou K, Glowienka E, Pouliot JF, Gullo G, Rietschel P. Freemantle N, et al. Among authors: wilson fr. Ther Adv Med Oncol. 2022 Jun 16;14:17588359221105024. doi: 10.1177/17588359221105024. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35747163 Free PMC article.
36 results